EFECTOS DE LA ADMINISTRACIÓN DE ALBÚMINA INTRAVENOSA SOBRE LA FUNCIÓN DIASTÓLICA DE LOS PACIENTES CON CIRROSIS HEPÁTICA.
- Conditions
- iver cirrhosis
- Registration Number
- EUCTR2005-005083-81-ES
- Lead Sponsor
- HOSPITAL CLINIC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Patients with cirrhosis of any etiology, except which than can also affect the cardiac function (like hemocromatosis, Wilson disease or amiloidosis)
Presence of diastolic dysfunction greater than stage 1 as determined by echocardiography
Absence of shock, bacterial infection or digestive hemorrhage at the moment of the inclusion or during the previous week
Age superior to18 and inferior to 75 years.
Absence of some of the exclusion criteria
Are the trial subjects under 18?
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years)
F.1.3.1 Number of subjects for this age range
Antecedents or presence of arterial hypertension that has required or no medical treatment.
Antecedents or presence of ischemic or valvular cardiopathy , cardiac arrhythmias, and peripheral vasculophaty.
Presence of severe anemia (Hb<9g/dL)
Presence of chronic ostrutive pulmonary diseases
Treatment with beta-blockers
Presence of Transjugular Intrahepatic Portosystemic Shunt (TIPS)
Pregnancy
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method